


CLAIMS


1. A compound represented by Formula 1:


[Formula 1]



wherein:




wherein R^1 to R^3 are each independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-10} alkoxy, substituted or unsubstituted C_{1-10} haloalkyl, substituted or unsubstituted C_{2-10} alkenyl, substituted or unsubstituted C_{2-10} alkynyl, substituted or unsubstituted C_{1-10} alkylene, substituted or unsubstituted C_{1-10} alkenylene, substituted or unsubstituted C_{1-10} alkynylene, substituted or unsubstituted C_{5-12} aryl, substituted or unsubstituted C_{7-12} arylalkyl, substituted or unsubstituted C_{5-14} arylalkynyl, substituted or unsubstituted C_{8-16} arylalkenyl, substituted or unsubstituted C_{3-10} heteroalkyl, substituted or unsubstituted C_{3-10} cycloalkyl, substituted or unsubstituted C_{3-10} heterocycloalkyl, or substituted or unsubstituted C_{5-12} heteroaryl, the heteroalkyl, heterocycloalkyl, or heteroaryl containing at least one of N, O, and S;

R^1 is selected from substituted or unsubstituted C_{1-6} alkyl, ,

, wherein n is an integer from 1 to 10;

R^2 is selected from hydrogen, substituted or unsubstituted C_{1-6} alkyl, and , wherein n is an integer from 1 to 10;

R^3 is selected from substituted or unsubstituted C_{1-6} alkyl,



, and $\text{C}(=\text{O})\text{NHR}_a$, wherein R_a is hydrogen or C_{1-6} alkyl, and n is an integer from 1 to 10;

~~the substitution refers to a substitution with a non-hydrogen substituent, the non-hydrogen substituent may be at least one selected from the group consisting of X_1 , R_a , O^- , $=O$, OR_a , SR_a , S^- , $N(R_a)_2$, $N^+(R_a)_3$, $=NR_a$, $C(X_1)_3$, CN , OCN , SCN , $N=C=O$, NCS , NO , NO_2 , $=N-OH$, $=N_2$, N_3 , $NHC(=O)R_a$, $C(=O)R_a$, $C(=O)NR_aR_a$, $S(=O)_2O^-$, $S(=O)_2OH$, $S(=O)_2R_a$, $OS(=O)_2OR_a$, $S(=O)_2NR_a$, $S(=O)R_a$, $OP(=O)(OR_a)_2$, $C(=O)R_a$, alkylene $C(=O)R_a$, $C(=S)R_a$, $C(=O)OR_a$, alkylene $C(=O)OR_a$, $C(=O)O^-$, alkylene $C(=O)O^-$, $C(=S)OR_a$, $C(=O)SR_a$, $C(=S)SR_a$, $C(=O)NR_aR_a$, alkylene $C(=O)NR_aR_a$, $C(=S)NR_aR_a$, and $C(NR_a)NR_aR_a$, X_1 is F, Cl, Br, or I, R_a is hydrogen, C_{1-6} alkyl, C_{5-12} aryl, C_{7-12} arylalkyl, or heterocycle,~~

R^4 is selected from substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{5-12} aryl, substituted or unsubstituted C_{7-12} arylalkyl, substituted or unsubstituted heterocycle, $-X_2$, O^- , $-CH_2OR_b$, and $-OR_b$;

~~R^4 and R^5 are each independently is selected from hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{5-12} aryl, substituted or unsubstituted C_{7-12} arylalkyl, substituted or unsubstituted heterocycle, $-X_2$, R_b , O^- , $=O$, $-CH_2OR_b$, OR_b and $-OR_b$,~~

X_2 is F, Cl, Br, or I,

R_b is H, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{5-12} aryl, substituted or unsubstituted C_{7-12} arylalkyl, or substituted or unsubstituted heterocycle,

R^6 is hydrogen or substituted or unsubstituted C_{1-6} alkyl, the substituent being $-C(=O)NH_2$,

R^7 is hydrogen or C_{1-6} alkyl, and

R^8 and R^9 are hydrogen or unsubstituted C_{1-6} alkyl;




further wherein, unless otherwise specified, when a group is substituted, it is substituted with a substituent selected from $-X_1$, $-R_j$, $-O^-$, $=O$, $-OR_j$, $-SR_j$, $-S^-$, $-N(R_j)_2$, $-N^+(R_j)_3$, $=NR_j$, $-C(X_1)_3$, $-CN$, $-OCN$, $-SCN$, $-N=C=O$, $-NCS$, $-NO$, $-NO_2$, $=N-OH$, $=N_2$, $-N_3$, $-NHC(=O)R_j$, $-C(=O)R_j$, $-C(=O)NR_jR_j$, $-S(=O)_2O^-$, $-S(=O)_2OH$, $-S(=O)_2R_j$, $-OS(=O)_2OR_j$, $-S(=O)_2NR_j$, $-$


S(=O)R_j, -OP(=O)(OR_j)₂, -C(=O)R_j, alkylene-C(=O)R_j, -C(=S)R_j, -C(=O)OR_j, alkylene-
C(=O)OR_j, -C(=O)O⁻, alkylene-C(=O)O⁻, -C(=S)OR_j, -C(=O)SR_j, -C(=S)SR_j, -
C(=O)NR_jR_i, alkylene-C(=O)NR_jR_i, -C(=S)NR_jR_i, and -C(-NR_j)NR_jR_i;

X₁ is F, Cl, Br, or I;

each occurrence of R_i is independently hydrogen, C₁₋₆ alkyl, C₅₋₁₂ aryl, C₇₋₁₂ arylalkyl, or heterocycle; and

further wherein the compound is not HyP-Gly-Gln-Asp-Gly-Leu-Ala-Gly-Pro-Lys.





5. The compound of claim 1, wherein R^4 is selected from the group consisting of $-\text{H}$, $-\text{OH}$, and $-\text{CH}_3$.
6. A compound selected from the group consisting of HyP-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Gln-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-His-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Lys-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ser-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Thr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ala-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Val-Gly-Leu-Ala-Gly-Pro-Lys, ~~HyP-Gly-Gln-Ile-Gly-Leu-Ala-Gly-Pro-Lys~~, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Phe-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Tyr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Trp-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ser(Homo)-Gly-Leu-Ala-Gly-Pro-Lys, D -Hyp(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, D -Hyp(2R,4S)-Gly- D -Gln- D -Leu-Gly- D -Leu- D -Ala-Gly- D -Pro- D -Lys, D -Hyp(2R, 4R)-Gly- D -Gln- D -Leu-Gly- D -Leu- D -Ala-Gly- D -Pro- D -Lys, HyP-Gly-Gln-Asp-Val-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ile-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Leu-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ala-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ser-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Thr-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Ala-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Leu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Glu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala, D -Hyp(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala, Hyp(2S,4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-hydroxyMe)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Fluoro)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Dimethyl)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (5-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Hyp-Gly-Ala-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Ala-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Ala-Pro-Lys, Hyp-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, D -


Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, and D -Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala.

7. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Xaa-Gly-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Glu, Asn, Gln, His, Lys, Ser, Thr, Ala, Val, Leu, Phe, Tyr, Trp, and homo-Ser.


8. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Asp-Xaa-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Val, Ile, Leu, Ala, Ser, and Thr.

9. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Xaa, wherein Xaa is selected from the group consisting of Leu, Glu, and Ala.

10. A peptide having an amino acid sequence represented by PD-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, wherein PD is any one selected from the group consisting of the following formulae:



11. A peptide having an amino acid sequence represented by PD-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, wherein PD is any one selected from the group consisting of the following formulae:




12. A peptide having any one amino acid sequence selected from the group consisting of Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Ala-Lys, Hyp-Gly-Gln-Glu-Gly-Lys-Gly, HyP-Gly-Gln-Leu-Gly-Leu, D -Hyp(2R, 4S)-Gly- D -Gln- D -Leu-Gly- D -Leu, HyP-Gly-Gln-Leu-Gly, HyP-Gly-Gln- D -

Leu-Gly, and D -HyP(2R, 4S)-Gly-Gln-Leu-Gly.


13. A compound represented by Formula 8:

[Formula 8]



14. A compound represented by Formula 10:

[Formula 10]



14. A pharmaceutical composition for use in the treatment of an eye disease, which comprises the compound according to any one of claims 1 to 6, 13, and 14, or the peptide according to any one of claims 7 to 12, as an active pharmaceutical ingredient.

15. Use of the compound according to any one of claims 1 to 6, 13, and 14, or the peptide according to any one of claims 7 to 12 in the manufacture of a pharmaceutical composition for treating an eye disease.

16. The use of claim 15, wherein the eye disease is one selected from the group consisting of retinopathy, keratitis, dry-macular degeneration, wet-macular degeneration, dry eye syndrome, heratoconjunctivitis sicca and keratoconjunctival epithelium disorder.